dr. rugo on vegf-a as an avastin response predictor
Published 12 years ago • 386 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
1:39
dr. rugo on anti-angiogenesis therapy response predictors
-
1:36
dr. rugo on the efficacy of bevacizumab in breast cancer
-
11:21
opthea: opt-302 (vegf-c/d trap) for combination treatment in namd and dme
-
1:03:04
vegf and anti-vegf in eye disease
-
7:05
vascular endothelial growth factor-a (vegf-a)
-
7:55
current role of vegf-targeted therapy in ovarian cancer
-
1:20
vegf-ax as a cancer inhibitor
-
13:46
choosing between vegf and egfr targeted therapy in mcrc
-
13:46
choosing between anti-vegf and anti-egfr targeted therapy
-
8:41
use of vegf-targeted tyrosine kinase inhibitors
-
0:53
dr. chan discusses the vegf-trap agent aflibercept
-
2:07
dr. tripathy discusses breast carcinoma heterogeneity
-
2:42
cediranib and lenalidomide in iodine 131-refractory differentiated thyroid cancer
-
1:46
dr. gupta on vegf inhibitors combined with immunotherapy in kidney cancer
-
7:43
mrcc: resistance to vegf and i/o
-
7:45
opthea: targeting a more complete blockade of vegf (ois@asrs 2016)
-
1:34:37
updating evidence-based, patient-centered care for dr/dme
-
4:17
blocking vegfr2 vs vegfa or vegfb in lung cancer
-
3:58
anti-vegf therapy in metastatic hcc